SE9401351D0 - A method for diagnosis - Google Patents

A method for diagnosis

Info

Publication number
SE9401351D0
SE9401351D0 SE9401351A SE9401351A SE9401351D0 SE 9401351 D0 SE9401351 D0 SE 9401351D0 SE 9401351 A SE9401351 A SE 9401351A SE 9401351 A SE9401351 A SE 9401351A SE 9401351 D0 SE9401351 D0 SE 9401351D0
Authority
SE
Sweden
Prior art keywords
pct
sec
human
date
individual
Prior art date
Application number
SE9401351A
Other languages
English (en)
Swedish (sv)
Inventor
Per Venge
Original Assignee
Venge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20393731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9401351(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Venge filed Critical Venge
Priority to SE9401351A priority Critical patent/SE9401351D0/xx
Publication of SE9401351D0 publication Critical patent/SE9401351D0/xx
Priority to EP95917540A priority patent/EP0756708B1/de
Priority to DE69521608T priority patent/DE69521608T2/de
Priority to US08/722,054 priority patent/US6136526A/en
Priority to DK95917540T priority patent/DK0756708T3/da
Priority to AU23551/95A priority patent/AU2355195A/en
Priority to JP52758295A priority patent/JP3544544B2/ja
Priority to PCT/SE1995/000439 priority patent/WO1995029404A1/en
Priority to ES95917540T priority patent/ES2160709T3/es
Priority to AT95917540T priority patent/ATE202849T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE9401351A 1994-04-21 1994-04-21 A method for diagnosis SE9401351D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis
AT95917540T ATE202849T1 (de) 1994-04-21 1995-04-21 Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl- antikörperzubereitung
ES95917540T ES2160709T3 (es) 1994-04-21 1995-04-21 Uso de lipocalina de neutrofilos humanos (hnl) como un marcador de diagnostico y preparacion de anticuerpo anti-hnl.
US08/722,054 US6136526A (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (HNL) as a diagnostic marker and anti-HNL-antibody preparation
DE69521608T DE69521608T2 (de) 1994-04-21 1995-04-21 Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl-antikörperzubereitung
EP95917540A EP0756708B1 (de) 1994-04-21 1995-04-21 Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl-antikörperzubereitung
DK95917540T DK0756708T3 (da) 1994-04-21 1995-04-21 Anvendelse af humant neutrophil-lipocalin (HNL) som en diagnostisk markør og anti-HNL-antistof-præparat
AU23551/95A AU2355195A (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation
JP52758295A JP3544544B2 (ja) 1994-04-21 1995-04-21 診断マーカーとしてのヒト好中球リポカリン（ｈｎｌ）の使用および抗−ｈｎｌ−抗体調製物
PCT/SE1995/000439 WO1995029404A1 (en) 1994-04-21 1995-04-21 Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis

Publications (1)

Publication Number Publication Date
SE9401351D0 true SE9401351D0 (sv) 1994-04-21

Family

ID=20393731

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9401351A SE9401351D0 (sv) 1994-04-21 1994-04-21 A method for diagnosis

Country Status (10)

Country Link
US (1) US6136526A (de)
EP (1) EP0756708B1 (de)
JP (1) JP3544544B2 (de)
AT (1) ATE202849T1 (de)
AU (1) AU2355195A (de)
DE (1) DE69521608T2 (de)
DK (1) DK0756708T3 (de)
ES (1) ES2160709T3 (de)
SE (1) SE9401351D0 (de)
WO (1) WO1995029404A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1143246A4 (de) * 1998-12-28 2004-11-24 Advance Kk System zum identifizieren von mikroorganismen
FI115165B (fi) 2001-06-04 2005-03-15 Aboatech Ab Oy Menetelmä infektion laadun määrittämiseksi
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
DE602004022150D1 (de) * 2003-03-27 2009-09-03 Childrens Hosp Medical Center Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
EP2272566A3 (de) 2003-08-18 2013-01-02 MedImmune, LLC Humanisierung von antikörpern
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
ES2818028T3 (es) * 2004-12-20 2021-04-09 Antibodyshop As Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
PL2035835T3 (pl) 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
WO2008017306A1 (en) 2006-08-07 2008-02-14 Antibodyshop A/S Diagnostic test to exclude significant renal injury
WO2008113363A1 (en) * 2007-03-21 2008-09-25 Bioporto Diagnostics A/S Diagnostic test for renal injury
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8846036B2 (en) * 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
ES2475990T5 (es) * 2007-11-15 2017-07-06 Bioporto Diagnostics A/S Uso diagnóstico de formas moleculares individuales de un biomarcador
EP2257813A4 (de) * 2008-03-12 2011-11-02 Univ Columbia Ngal mit hohem molekulargewicht als biomarker für chronische nierenerkrankung
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
KR101939964B1 (ko) 2008-11-21 2019-01-18 퓨처 메디칼 다이아그노스틱스 코 엘티디 급성 신장 손상의 발견 또는 감시 방법, 장치 및 키트
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
US9709565B2 (en) 2010-04-21 2017-07-18 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
CN108802385B (zh) 2012-02-09 2022-02-08 米密德诊断学有限公司 用于诊断感染的标记和决定因素和其使用方法
EP2925337B1 (de) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutante ngal-proteine und verwendungen davon
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
RU2758608C2 (ru) * 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Способ диагностики с использованием hnl
CN107209184B (zh) 2014-12-11 2020-04-24 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
EP3423590A4 (de) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. Rna-determinanten zur unterscheidung zwischen bakteriellen und viralen infektionen
IL294121B2 (en) 2016-03-03 2023-09-01 Memed Diagnostics Ltd An RNA test to diagnose the type of infection
WO2018001932A1 (en) 2016-06-30 2018-01-04 Koninklijke Philips N.V. Device, system and method for detecting an analyte in a body fluid sample containing a plurality of cells
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2024246048A1 (en) 2023-06-01 2024-12-05 P & M Venge Ab Specific detection of homodimeric hnl
CN119375492B (zh) * 2024-12-27 2025-05-30 北京水木翼锋诊断技术有限公司 Hnl在制备用于鉴定血流感染的试剂中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US5200319A (en) * 1989-10-27 1993-04-06 The General Hospital Corporation Diagnosis of glomerulonephritis

Also Published As

Publication number Publication date
EP0756708A1 (de) 1997-02-05
JP3544544B2 (ja) 2004-07-21
JPH09512630A (ja) 1997-12-16
DE69521608D1 (de) 2001-08-09
EP0756708B1 (de) 2001-07-04
AU2355195A (en) 1995-11-16
WO1995029404A1 (en) 1995-11-02
DE69521608T2 (de) 2002-05-08
DK0756708T3 (da) 2001-10-29
US6136526A (en) 2000-10-24
ES2160709T3 (es) 2001-11-16
ATE202849T1 (de) 2001-07-15

Similar Documents

Publication Publication Date Title
SE9401351D0 (sv) A method for diagnosis
Jepsen et al. Progressive peri‐implantitis. Incidence and prediction of peri‐implant attachment loss.
Isaza‐Guzmán et al. Salivary levels of NLRP3 inflammasome‐related proteins as potential biomarkers of periodontal clinical status
Zahavi et al. Enhanced in vivo platelet “release reaction” in old healthy individuals
Plagnat et al. Elastase, α2‐macroglobulin and alkaline phosphatase in crevicular fluid from implants with and without periimplantitis
Kaldahl et al. Relationship of gingival bleeding, gingival suppuration, and supragingival plaque to attachment loss
Greenstein The role of bleeding upon probing in the diagnosis of periodontal disease: a literature review
Grbic et al. Risk indicators for future clinical attachment loss in adult periodontitis. Patient variables
DE69521813D1 (de) Verfahrens und testsätze zur diagnose periodentahlkrankheiten und zur vorhersage des risikos der progression davon
Balli et al. Assessment of periostin levels in serum and gingival crevicular fluid of patients with periodontal disease
Dabra et al. Evaluating the levels of salivary alkaline and acid phosphatase activities as biochemical markers for periodontal disease: A case series
Oringer et al. C‐Telopeptide pyridinoline cross‐links (ICTP (and periodontal pathogens associated with endosseous oral implants
Talonpoika et al. Type I collagen carboxyterminal telopeptide in human gingival crevicular fluid in different clinical conditions and after periodontal treatment
DK0792458T3 (da) Fremgangsmåder til hjælp ved diagnosen af Alzheimers sygdom ved måling af amyloid-betapeptid (x->41) og tau
Witzel et al. Reconstructing impairment of secretory ameloblast function in porcine teeth by analysis of morphological alterations in dental enamel
JP7245174B2 (ja) 唾液のｈｇｆ及びｍｍｐ－８に基づく歯周炎の診断
Ralls et al. Problems in identifying “bursts” of periodontal attachment loss
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
Melamed et al. Type A behavior, tension, and ambulatory cardiovascular reactivity in workers exposed to noise stress.
Gupta et al. The influence of type 2 diabetes mellitus on salivary matrix metalloproteinase-8 levels and periodontal parameters: a study in an Indian population
Best et al. Reliability of attachment loss measurements in a longitudinal clinical trial
Rudra Mohan et al. The effect of nonsurgical periodontal therapy on pentraxin 3 levels in smokers and nonsmokers with chronic periodontitis
Collares et al. Proximal restoration increases the risk of clinical attachment loss
AU635050B2 (en) Method for diagnosis of periodontal disease by detection of alanine aminotransferase
Lachmann et al. Reliability of findings around healthy implants in association with oral hygiene measures: A clinical, microbiological, and immunological follow‐up in edentulous patients